Bioceres S.A. BIOX 深 沪
等待开盘 07-18 09:30:00 美东时间
3.78
-0.030
-0.79%
华盛通- 最 高3.84
- 今 开3.81
- 成交量 10.12万股
- 最 低 3.72
- 昨 收 3.81
- 总市值 2.29亿
- 52周最高 11.4091
- 市盈率 静 73.97
- 换手率 0.17%
- 52周最低 3.51
- 委 比 21.57%
- 总股本 6045.28万
- 历史最高 17.94
- 量 比 1.32
- 振 幅 3.15%
- 历史最低 3.51
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
BioCardia, Inc. announced that Henry Ford Health in Detroit is enrolling patients with ischemic HFrEF in the CardiAMP HF II trial, a pivotal study for autologous bone marrow-derived mononuclear cell therapy. The trial aims to confirm the safety and efficacy of this therapy, which promotes microvascular repair and improves heart function. CardiAMP HF II is a 250-patient, randomized, multicenter, placebo-controlled study targeting patients on guide...
07-16 12:45
美股大行评级 | 潜在涨幅118.39%！花旗上调Ducommun目标价至190美元，维持"买入"评级
今日重点评级关注：花旗：维持Ducommun"买入"评级，目标价从186美元升至190美元；摩根大通：维持Sunrun"超配"评级，目标价从13美元升至16美元
07-16 08:33
Oppenheimer Maintains Outperform on Bioceres Crop Solutions, Lowers Price Target to $6
Oppenheimer analyst Kristen Owen maintains Bioceres Crop Solutions (NASDAQ:BIOX) with a Outperform and lowers the price target from $7 to $6.
07-16 01:38
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica Inc. appoints Scott Madel as Chief Commercial Officer, leveraging his 20+ years of experience in healthcare diagnostics and organizational growth. Madel successfully led turnarounds and scaled revenues at Boston Heart Diagnostics and Genova Diagnostics. He will drive commercialization of inFoods® IBS, a diagnostic-guided therapy for identifying food triggers in gastrointestinal conditions. Published clinical trials demonstrate its effic...
06-26 12:19
电话会总结 ｜ Bioceres Q3 2025 业绩电话会核心要点
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote> <p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： Bioceres Crop Solutions (BIOX) 在2025财年第三季度实现总收入6060万美元，同比下降27.9%（去年同期为8400万美元）。毛利润为2400万美元，同比下降43.7%（去年同期为4260万美元）。调整后EBITDA为900万美元，同比下降57.4%（去年同期为2110万美元）。此外，经营活动产生的净现金流为2330万美元，相较去年同期的1700万美元净流出，改善了4070万美元。<
06-05 12:09
电话会总结 ｜ Bioceres Q3 2025 业绩电话会核心要点
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote> <p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： - Bioceres Crop Solutions (BIOX) 在2025财年第三季度的总收入为6060万美元，同比下降27.9%，去年同期为8400万美元。 - 毛利润为2400万美元，同比下降43.7%，去年同期为4260万美元。 - 调整后EBITDA为900万美元，同比下降57.4%，去年同期为2110万美元。 - 经营活动产生的净现金流为2330万美元，相较去年同期的净流出1700万美元，改善了4070
06-05 12:08
BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor
BioSig Technologies acquired Streamex Exchange Corporation and appointed Sean Roosen as Strategic Advisor. With over 30 years of experience in mining and resource ventures, Roosen brings significant expertise to Streamex’s mission of revolutionizing commodity markets through tokenized assets. Streamex’s advisory board also includes Frank Giustra and Mathew August, further strengthening its leadership in real-world asset tokenization.
06-04 12:25
BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer
<p>BioSig Technologies, Inc. acquired Streamex Exchange Corporation and appointed Mitch Williams as Chief Investment Officer. With over 20 years of experience in capital markets, Williams will lead the company’s strategic vision in tokenizing real-world assets and bringing commodity markets on-chain. Streamex aims to revolutionize commodity finance by enhancing liquidity and efficiency through blockchain technology.</p>
05-28 17:46
Bioceres Crop Solutions Q3 GAAP EPS $(0.04) Beats $(0.09) Estimate, Sales $60.60M Miss $63.93M Estimate
Bioceres Crop Solutions (NASDAQ:BIOX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 126.67 percent decrease over earnings of $0.15 per
05-21 21:55
Bioceres reports Q3 results
Bioceres press release (NASDAQ:BIOX): Q3 net loss was $1.6 million Revenue of $60.6M (-27.9% Y/Y). Total revenues were $60.6 million in 3Q25, compared to $84.0 million for the same quarter last year, ...
05-21 19:06
